238 related articles for article (PubMed ID: 24927408)
1. The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.
Staudinger M; Glorius P; Burger R; Kellner C; Klausz K; Günther A; Repp R; Klapper W; Gramatzki M; Peipp M
Blood Cancer J; 2014 Jun; 4(6):e219. PubMed ID: 24927408
[TBL] [Abstract][Full Text] [Related]
2. The novel multispecies Fc-specific Pseudomonas exotoxin A fusion protein α-Fc-ETA' enables screening of antibodies for immunotoxin development.
Klausz K; Kellner C; Derer S; Valerius T; Staudinger M; Burger R; Gramatzki M; Peipp M
J Immunol Methods; 2015 Mar; 418():75-83. PubMed ID: 25701195
[TBL] [Abstract][Full Text] [Related]
3. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.
Tur MK; Huhn M; Thepen T; Stöcker M; Krohn R; Vogel S; Jost E; Osieka R; van de Winkel JG; Fischer R; Finnern R; Barth S
Cancer Res; 2003 Dec; 63(23):8414-9. PubMed ID: 14679004
[TBL] [Abstract][Full Text] [Related]
4. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model.
Tur MK; Huhn M; Jost E; Thepen T; Brümmendorf TH; Barth S
Int J Cancer; 2011 Sep; 129(5):1277-82. PubMed ID: 21077160
[TBL] [Abstract][Full Text] [Related]
5. Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13-ETA' and the bispecific scFv [13xds16].
Grieger E; Gresch G; Niesen J; Woitok M; Barth S; Fischer R; Fendel R; Stein C
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2159-2170. PubMed ID: 28669053
[TBL] [Abstract][Full Text] [Related]
6. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
Bruell D; Bruns CJ; Yezhelyev M; Huhn M; Müller J; Ischenko I; Fischer R; Finnern R; Jauch KW; Barth S
Int J Mol Med; 2005 Feb; 15(2):305-13. PubMed ID: 15647848
[TBL] [Abstract][Full Text] [Related]
7. Construction and in vitro evaluation of RFT5(scFv)-ETA', a new recombinant single-chain immunotoxin with specific cytotoxicity toward CD25+ Hodgkin-derived cell lines.
Barth S; Huhn M; Wels W; Diehl V; Engert A
Int J Mol Med; 1998 Jan; 1(1):249-56. PubMed ID: 9852227
[TBL] [Abstract][Full Text] [Related]
8. Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer.
Kessler C; Pardo A; Tur MK; Gattenlöhner S; Fischer R; Kolberg K; Barth S
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2025-2038. PubMed ID: 28667390
[TBL] [Abstract][Full Text] [Related]
9. A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells.
Schwemmlein M; Peipp M; Barbin K; Saul D; Stockmeyer B; Repp R; Birkmann J; Oduncu F; Emmerich B; Fey GH
Br J Haematol; 2006 Apr; 133(2):141-51. PubMed ID: 16611304
[TBL] [Abstract][Full Text] [Related]
10. Construction, expression, and activity of a novel immunotoxin comprising a humanized antiepidermal growth factor receptor scFv and modified Pseudomonas aeruginosa exotoxin A.
Akbari B; Farajnia S; Zarghami N; Mahdieh N; Rahmati M; Khosroshahi SA; Barzegar A; Rahbarnia L
Anticancer Drugs; 2017 Mar; 28(3):263-270. PubMed ID: 27861173
[TBL] [Abstract][Full Text] [Related]
11. Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia.
Fitting J; Blume T; Ten Haaf A; Blau W; Gattenlöhner S; Tur MK; Barth S
MAbs; 2015; 7(2):390-402. PubMed ID: 25760770
[TBL] [Abstract][Full Text] [Related]
12. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity.
Di Paolo C; Willuda J; Kubetzko S; Lauffer I; Tschudi D; Waibel R; Plückthun A; Stahel RA; Zangemeister-Wittke U
Clin Cancer Res; 2003 Jul; 9(7):2837-48. PubMed ID: 12855664
[TBL] [Abstract][Full Text] [Related]
13. Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors.
Singh R; Samant U; Hyland S; Chaudhari PR; Wels WS; Bandyopadhyay D
Mol Cancer Ther; 2007 Feb; 6(2):562-9. PubMed ID: 17308054
[TBL] [Abstract][Full Text] [Related]
14. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells.
Peipp M; Küpers H; Saul D; Schlierf B; Greil J; Zunino SJ; Gramatzki M; Fey GH
Cancer Res; 2002 May; 62(10):2848-55. PubMed ID: 12019163
[TBL] [Abstract][Full Text] [Related]
15. Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A.
Kaplan G; Lee F; Onda M; Kolyvas E; Bhardwaj G; Baker D; Pastan I
Toxins (Basel); 2016 Jul; 8(8):. PubMed ID: 27463727
[TBL] [Abstract][Full Text] [Related]
16. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
[TBL] [Abstract][Full Text] [Related]
17. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.
Niesen J; Stein C; Brehm H; Hehmann-Titt G; Fendel R; Melmer G; Fischer R; Barth S
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2079-95. PubMed ID: 25899161
[TBL] [Abstract][Full Text] [Related]
18. CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma.
Barth S; Matthey B; Huhn M; Diehl V; Engert A
Cytokines Cell Mol Ther; 1999 Jun; 5(2):69-78. PubMed ID: 10515679
[TBL] [Abstract][Full Text] [Related]
19. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity.
Martin-Killias P; Stefan N; Rothschild S; Plückthun A; Zangemeister-Wittke U
Clin Cancer Res; 2011 Jan; 17(1):100-10. PubMed ID: 21075824
[TBL] [Abstract][Full Text] [Related]
20. Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development.
Kellner C; Bleeker WK; Lammerts van Bueren JJ; Staudinger M; Klausz K; Derer S; Glorius P; Muskulus A; de Goeij BE; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Aug; 371(1-2):122-33. PubMed ID: 21756911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
